Form 4: INSMED Chief Legal Officer Receives Equity Awards

INSMED Inc.'s Chief Legal Officer, Michael Alexander Smith, was granted 5,293 Restricted Stock Units and 27,600 stock options on January 2, 2026, as part of the company's incentive plan.

Summary

• Michael Alexander Smith, Chief Legal Officer of INSMED Inc. (INSM), reported changes in beneficial ownership.
• On January 2, 2026, Mr. Smith acquired 5,293 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• These RSUs were granted for no consideration under the Company's Amended and Restated 2019 Incentive Plan.
• The RSUs vest 25% on the first day of the first month following the first anniversary of the grant date (Initial Vesting Date) and 25% on each subsequent anniversary until fully vested.
• Following this transaction, Mr. Smith beneficially owns 60,195 shares of Common Stock directly.
• Additionally, on January 2, 2026, Mr. Smith acquired 27,600 stock options with an exercise price of $177.12.
• These stock options were also granted under the Company's Amended and Restated 2019 Incentive Plan and have an expiration date of January 2, 2036.
• The options vest 25% on the Initial Vesting Date and an additional 12.5% every six months thereafter until fully vested.
• Following this transaction, Mr. Smith beneficially owns 27,600 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The filing reports routine executive compensation in the form of equity grants. This is generally a neutral event but can be seen as slightly positive as it aligns management's long-term interests with shareholders.

Positives

• The grant of Restricted Stock Units and stock options aligns the Chief Legal Officer's financial interests with those of the shareholders, incentivizing long-term performance.
• The equity awards are part of a pre-existing, approved incentive plan, indicating a structured approach to executive compensation.

Future Outlook

The equity awards granted to the Chief Legal Officer are subject to multi-year vesting schedules, indicating a long-term incentive structure. The RSUs vest 25% annually after an initial one-year period, and stock options vest 25% initially, followed by 12.5% every six months.

Industry Context

The granting of Restricted Stock Units and stock options to key executives is a common practice in the biotechnology and pharmaceutical industries, including companies like INSMED Inc., to attract, retain, and motivate talent while aligning executive interests with shareholder value creation. This is a standard component of executive compensation packages.

Comparison to Industry Standards

• The use of a combination of Restricted Stock Units (RSUs) and stock options for executive compensation is a widely adopted practice across the U.S. public company landscape, particularly in growth-oriented sectors like biotechnology.
• Vesting schedules, such as the 25% annual vesting for RSUs after an initial cliff and periodic vesting for options, are typical and designed to promote long-term retention and performance.
• The grant of equity for no consideration (for RSUs) and at a market-based exercise price (for options) is standard for incentive plans.

Corporate Governance

Related Party Transactions

• The equity grants to Michael Alexander Smith, Chief Legal Officer, represent compensation from the company, which is a form of related party transaction common in executive compensation.

Stakeholder Impact

• Shareholders: The equity grants are designed to align the Chief Legal Officer's long-term interests with shareholder value creation, potentially leading to more focused management decisions.
• Employees: The incentive plan provides a framework for executive compensation, which can influence overall compensation philosophy within the company.

Next Steps

• The granted Restricted Stock Units will begin vesting 25% on the first day of the first month following the first anniversary of the grant date (January 2, 2026), and 25% on each subsequent anniversary until fully vested.
• The granted stock options will become exercisable 25% on the Initial Vesting Date and an additional 12.5% every six months thereafter until fully vested.

Key Dates

Keywords

INSMED Inc., INSM, Michael Alexander Smith, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, Beneficial Ownership, Equity Awards